Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onartuzumab - Genentech

Drug Profile

Onartuzumab - Genentech

Alternative Names: 5D5; anti-c-Met monoclonal antibody - Genentech; hOA-5D5.v2; MetMAb; OA-5D5; PRO-143966; RG-3638; RO-5490258

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastric cancer; Glioblastoma; Liver cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 19 Jul 2018 Roche completes a phase III extension trial for Solid tumours in Latvia, Spain, France, Russia, Italy, Japan, Serbia and South Africa (NCT02488330)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2016 Genentech completes a phase II trial in Breast cancer (First-line therapy, second-line therapy or greater, metastatic disease, combination therapy) in USA, Belgium, France, Germany, Spain and United Kingdom (IV) (NCT01186991)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top